Donald J. Griffith
Chief Financial Officer, Director · Sonnet BioTherapeutics Holdings, Inc.
Individual
- 2024
- Dec 3, 2025
- 3
Other insiders active in the same sector
No other insider has filed at Donald J. Griffith's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Forbion Growth Opportunities Fund III Cooperatief U.A. - $64.80M in BRVE purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $63.45M in SEPN purchases and sales in the last 12 months
- BVF PARTNERS L P - $62.96M in MLTX purchases and sales in the last 12 months
- Mario Schlosser - $62.90M in OSCR purchases and sales in the last 12 months
- BROADWOOD PARTNERS, L.P. - $62.75M in STAA purchases and sales in the last 12 months
- Jonathan M. Rothberg - $62.19M in BFLY purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Donald J. Griffith?
Donald J. Griffith is a corporate insider, tracked as Chief Financial Officer, Director of Sonnet BioTherapeutics Holdings, Inc. (SONN). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Donald J. Griffith last file a Form 4?
The most recent primary Form 4 on record is dated 3 December 2025, one of 3 filings going back to 2024.
